The University of Texas Health Science Center, Houston Report issue

Academic/Hospital Phase 2
Founded: Houston Texas United States (1972)

Organization Overview

First Clinical Trial
2011
NCT01464788
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Andrew D. Barreto, MD | Joseph Anthony Lucci III | Rabih Said | Robert J Amato

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Cervical Intraepithelial Neoplasia (Phase 2)

Ischemia (Phase 2)

Melanoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Stroke (Phase 2)

Uterine Cervical Dysplasia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 8